Voyager Therapeutics, Inc.
- Market Cap (Float-Adj) (Float-adjusted market cap computed by the low-float screener — matches the screener row. May differ from the standard cap (price × all shares outstanding) reported elsewhere.)
- $201.5M
- Price
- $3.33
- % Change (Daily % change from the live per-ticker quote feed.)
- +0.45%
- Volume
- 74.1K
About
Voyager Therapeutics, Inc., a gene therapy company, focuses on the development of treatments and next-generation platform technologies. The company's lead clinical candidate is the VY-AADC, which is in open-label Phase 1 clinical trial for the treatment of Parkinson's disease. Its preclinical programs comprise VY-SOD102 for the treatment of amyotrophic lateral sclerosis; VY-HTT01 for Huntington's disease; VY-FXN01 for Friedreich's ataxia; and Tau program for the treatment of tauopathies, including Alzheimer's disease, progressive supranuclear palsy, and frontotemporal dementia, as well as for spinal muscular atrophy. The company has collaboration and license agreements with Neurocrine Biosciences, Inc., Pfizer Inc., and Novartis Pharma, A.G. for the research, development, and commercialization of adeno-associated virus gene therapy products. Voyager Therapeutics, Inc. was incorporated in 2013 and is headquartered in Cambridge, Massachusetts.
Quick stats
Shares outstanding60.4M
Computed float4.7M
Float / shares7.8%
Key info
SectorHealthcare
IndustryBiotechnology
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0001640266
AI Summary
AI-generated1/13
standardbullishearnings
Voyager Reports Second Quarter 2026 Financial and Operating Results
Voyager reported a narrower Q2 net loss of $24.5 million, compared to $33.4 million in the prior year, driven by program prioritization and reduced G&A expenses.
The company ended the quarter with $149 million in cash, sufficient to fund operations into 2028, while achieving IND clearance for VY1706 with dosing expected in Q4.
Pipeline progress includes anticipated tau PET data for VY7523 in Q4 and a planned H2 2026 clinical trial start for partner Neurocrine’s NBIB-‘223 program.
Red flags
- Collaboration revenue decreased to $3.2 million from $5.2 million due to transition beyond the research phase with Neurocrine